| scholarly article | Q13442814 |
| P50 | author | Stig Egil Bojesen | Q72992763 |
| Jørgen Vestbo | Q41838693 | ||
| Morten Dahl | Q42881232 | ||
| Børge G. Nordestgaard | Q43530123 | ||
| Anne Tybjærg-Hansen | Q52932605 | ||
| P2093 | author name string | Peter Lange | |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chronic obstructive pulmonary disease | Q199804 |
| P304 | page(s) | 250-255 | |
| P577 | publication date | 2006-10-19 | |
| P1433 | published in | American Journal of Respiratory and Critical Care Medicine | Q4744267 |
| P1476 | title | C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease | |
| P478 | volume | 175 |
| Q55054583 | 8th international conference on management and rehabilitation of chronic respiratory failure: the long summaries – part 1. |
| Q36945570 | A Multidimensional Risk Score to Predict All-Cause Hospitalization in Community-Dwelling Older Individuals With Obstructive Lung Disease |
| Q37822219 | Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine |
| Q40623148 | Airflow obstruction, atherosclerosis and cardiovascular risk factors in the AGES Reykjavik study |
| Q37641498 | Airway gene expression of IL-1 pathway mediators predicts exacerbation risk in obstructive airway disease. |
| Q44305758 | American Thoracic Society Annual International Congress |
| Q38937853 | An ECLIPSE View of Alpha-1 Antitrypsin Deficiency |
| Q48390718 | An index of daily step count and systemic inflammation predicts clinical outcomes in chronic obstructive pulmonary disease |
| Q38066244 | An omics strategy for discovering pulmonary biomarkers potentially relevant to the evaluation of tobacco products |
| Q92218965 | Analysis of the level of selected parameters of inflammation, circulating immune complexes, and related indicators (neutrophil/lymphocyte, platelet/lymphocyte, CRP/CIC) in patients with obstructive diseases |
| Q58840453 | Anti-Tissue Antibodies Are Related to Lung Function in Chronic Obstructive Pulmonary Disease |
| Q38670757 | Application of nitric oxide measurements in clinical conditions beyond asthma |
| Q93075758 | Association between blood pressure, inflammation and spirometry parameters in chronic obstructive pulmonary disease |
| Q35421066 | Association of CRP and IL-6 with lung function in a middle-aged population initially free from self-reported respiratory problems: the Whitehall II study |
| Q36149225 | Association of cigarette smoking and CRP levels with DNA methylation in α-1 antitrypsin deficiency. |
| Q36967440 | Association of the Neutrophil-to-Lymphocyte Ratio with Lung Function and Exacerbations in Patients with Chronic Obstructive Pulmonary Disease |
| Q33481269 | Associations between statins and COPD: a systematic review. |
| Q38644007 | Asthma and chronic obstructive pulmonary disease overlap: asthmatic chronic obstructive pulmonary disease or chronic obstructive asthma? |
| Q36535142 | Biobehavioral Prognostic Factors in Chronic Obstructive Pulmonary Disease: Results From the INSPIRE-II Trial |
| Q42764832 | Biomarkers in COPD: time for a deep breath |
| Q47112547 | Biomarkers of collagen turnover are related to annual change in FEV1 in patients with chronic obstructive pulmonary disease within the ECLIPSE study |
| Q37937720 | Biomarkers of therapeutic response in patients with chronic obstructive pulmonary disease: a critical review of the literature |
| Q37012728 | Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease |
| Q38109057 | Blood specimen biomarkers of inflammation, matrix degradation, angiogenesis, and cardiac involvement: a future useful tool in assessing clinical outcomes of COPD patients in clinical practice? |
| Q84112341 | C reactive protein and alpha1-antitrypsin: relationship between levels and gene variants |
| Q44785204 | C-Reactive Protein at Discharge, Diabetes Mellitus and ≥ 1 Hospitalization During Previous Year Predict Early Readmission in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease |
| Q37568497 | C-Reactive Protein in Stable Cystic Fibrosis: An Additional Indicator of Clinical Disease Activity and Risk of Future Pulmonary Exacerbations |
| Q39278432 | C-reactive protein as a prognostic marker in chronic obstructive pulmonary disease |
| Q36029240 | C-reactive protein levels in stable COPD patients: a case-control study |
| Q49148594 | C-reactive protein levels, haplotypes, and the risk of incident chronic obstructive pulmonary disease. |
| Q42268471 | C-reactive protein measurements as a marker of the severity of chronic obstructive pulmonary disease exacerbations |
| Q35637295 | COPD association and repeatability of blood biomarkers in the ECLIPSE cohort |
| Q42255529 | Calprotectin--a marker of mortality in COPD? Results from a prospective cohort study |
| Q38752544 | Can we predict the prognosis of COPD with a routine blood test? |
| Q40927408 | Cancer antigen-125 levels predict long-term mortality in chronic obstructive pulmonary disease. |
| Q37103712 | Cardiac disease in chronic obstructive pulmonary disease |
| Q37098445 | Cardiovascular injury and repair in chronic obstructive pulmonary disease |
| Q26766294 | Challenges and Current Efforts in the Development of Biomarkers for Chronic Inflammatory and Remodeling Conditions of the Lungs |
| Q92589961 | Chemokines in COPD: From Implication to Therapeutic Use |
| Q35312449 | Chest CT measures of muscle and adipose tissue in COPD: gender-based differences in content and in relationships with blood biomarkers |
| Q36402823 | Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony |
| Q48393784 | Chronic obstructive pulmonary disease and obstructive sleep apnea: overlaps in pathophysiology, systemic inflammation, and cardiovascular disease |
| Q36405415 | Chronic obstructive pulmonary disease phenotype desaturator with hypoxic vascular remodelling and pulmonary hypertension obtained by cluster analysis. |
| Q33448971 | Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer |
| Q55387022 | Clinical utility of blood neutrophil-lymphocyte ratio in Japanese COPD patients. |
| Q39174951 | Cognitive function in chronic obstructive pulmonary disease: relationship to global initiative for chronic obstructive lung disease 2011 categories |
| Q39827516 | Coma and Stroke Following Surgical Treatment of Unruptured Intracranial Aneurysm: An American College of Surgeons National Surgical Quality Improvement Program Study |
| Q33722392 | Combined Bone Marrow-Derived Mesenchymal Stromal Cell Therapy and One-Way Endobronchial Valve Placement in Patients with Pulmonary Emphysema: A Phase I Clinical Trial. |
| Q38867042 | Convergence in the Epidemiology and Pathogenesis of COPD and Pneumonia. |
| Q51645692 | Correlation between decrease of CRP and resolution of airway inflammatory response, improvement of health status, and clinical outcomes during severe acute exacerbation of chronic obstructive pulmonary disease. |
| Q37109900 | Determinants of lung volumes in chronic spinal cord injury |
| Q34215069 | Determination of inflammatory biomarkers in patients with COPD: a comparison of different assays. |
| Q38770013 | Diagnosis and investigation in the severe asthma clinic. |
| Q43452631 | Differences in local and systemic inflammatory markers in patients with obstructive airways disease |
| Q45817425 | Dysregulated adipokine metabolism in chronic obstructive pulmonary disease |
| Q48461345 | Effect of bronchial colonisation on airway and systemic inflammation in stable COPD. |
| Q24635347 | Effect of doxycycline in patients of moderate to severe chronic obstructive pulmonary disease with stable symptoms |
| Q37636173 | Effects of inhaled therapy on biomarkers of systemic inflammation in stable chronic obstructive pulmonary disease |
| Q40986838 | Evaluation of platelet lymphocyte ratio and 90-day mortality in patients with acute exacerbation of chronic obstructive pulmonary disease |
| Q55353829 | Expansion of a Population of Large Monocytes (Atypical Monocytes) in Peripheral Blood of Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Diseases. |
| Q45440477 | Expression of interleukin (IL)-10, IL-17A and IL-22 in serum and sputum of stable chronic obstructive pulmonary disease patients |
| Q50883932 | Fetuin-A is associated with disease severity and exacerbation frequency in patients with COPD. |
| Q41454775 | Fibrinogen and α1-antitrypsin in COPD exacerbations |
| Q84488849 | From BODE to ADO to outcomes in multimorbid COPD patients |
| Q36419791 | Health-related quality of life and long-term prognosis in chronic hypercapnic respiratory failure: a prospective survival analysis |
| Q39818617 | High body mass index and risk of exacerbations and pneumonias in individuals with chronic obstructive pulmonary disease: observational and genetic risk estimates from the Copenhagen General Population Study |
| Q58775176 | High-sensitivity C-reactive protein in heart failure with preserved ejection fraction |
| Q41831767 | HsCRP in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease |
| Q35023212 | Hypoxemia in patients with COPD: cause, effects, and disease progression |
| Q38710985 | Implications of the inflammatory response for the identification of biomarkers of chronic obstructive pulmonary disease. |
| Q33640782 | Inadequate glucose control in type 2 diabetes is associated with impaired lung function and systemic inflammation: a cross-sectional study |
| Q39967582 | Increased daily movement associates with reduced mortality among COPD patients having systemic inflammation |
| Q43544835 | Increased levels of soluble ICAM-1 in chronic obstructive pulmonary disease and resistant smokers are related to active smoking |
| Q26830867 | Inflammation and Nutritional Science for Programs/Policies and Interpretation of Research Evidence (INSPIRE). |
| Q57955696 | Inflammatory Biomarkers Improve Clinical Prediction of Mortality in Chronic Obstructive Pulmonary Disease |
| Q36383938 | Inflammatory and repair serum biomarker pattern: association to clinical outcomes in COPD. |
| Q48611059 | Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. |
| Q36036012 | Inflammatory markers and mortality among US adults with obstructive lung function |
| Q30491209 | Inflammatory status and lung function predict mortality in lung cancer screening participants |
| Q37153293 | Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease |
| Q43081658 | Interleukin-6 and statin therapy: potential role in the management of COPD. |
| Q41496258 | Long-term treatment with budesonide/formoterol attenuates circulating CRP levels in chronic obstructive pulmonary disease patients of group D |
| Q37396158 | Longitudinal association of C-reactive protein and lung function over 13 years: The EPIC-Norfolk study |
| Q35127672 | Low oxygen saturation and mortality in an adult cohort: the Tromsø study. |
| Q37168317 | Markers of early disease and prognosis in COPD. |
| Q34778477 | Matrix metalloproteinase-9 predicts pulmonary status declines in α1-antitrypsin deficiency |
| Q47722208 | Menopause, lung function and obstructive lung disease outcomes: a systematic review. |
| Q36476007 | Mental health, serum biomarkers and survival in severe COPD: a pilot study |
| Q43014156 | Microalbuminuria and hypoxemia in patients with chronic obstructive pulmonary disease |
| Q37360329 | Midregional pro-adrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational study |
| Q93126824 | Molecular Characteristics and Treatment of Endothelial Dysfunction in Patients with COPD: A Review Article |
| Q37790366 | Mortality in COPD: causes, risk factors, and prevention. |
| Q33796180 | Multiple biomarkers predict disease severity, progression and mortality in COPD. |
| Q89921656 | Nebulized heparin and salbutamol versus Salbutamol alone in acute exacerbation of chronic obstructive pulmonary disease requiring mechanical ventilation: a double blind randomised controlled trial |
| Q37055378 | Neutrophil-to-lymphocyte ratio has a close association with gangrenous appendicitis in patients undergoing appendectomy |
| Q35530179 | Neutrophil-to-lymphocyte ratio, calprotectin and YKL-40 in patients with chronic obstructive pulmonary disease: correlations and 5-year mortality - a cohort study |
| Q37153279 | New concepts in the pathobiology of chronic obstructive pulmonary disease |
| Q36059697 | Perforin, granzyme B, and FasL expression by peripheral blood T lymphocytes in emphysema |
| Q34280020 | Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype |
| Q36777597 | Phenotyping of chronic obstructive pulmonary disease using the modified Bhalla scoring system for high-resolution computed tomography |
| Q45905529 | Plasma C-reactive protein levels correlate with markers of airway inflammation after lung transplantation: a role for systemic inflammation in bronchiolitis obliterans syndrome? |
| Q35794462 | Plasma Chemokine signature correlates with lung goblet cell hyperplasia in smokers with and without chronic obstructive pulmonary disease |
| Q35077055 | Plasma YKL-40 and all-cause mortality in patients with chronic obstructive pulmonary disease. |
| Q37224504 | Plasma homocysteine is elevated in COPD patients and is related to COPD severity |
| Q37722931 | Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function |
| Q37007407 | Potential mechanisms linking atherosclerosis and increased cardiovascular risk in COPD: focus on Sirtuins. |
| Q40448715 | Predicting In-Hospital Treatment Failure (≤ 7 days) in Patients with COPD Exacerbation Using Antibiotics and Systemic Steroids. |
| Q38823010 | Prediction and prevention of exacerbations and mortality in patients with COPD. |
| Q91866074 | Predictive Value of Combining Inflammatory Biomarkers and Rapid Decline of FEV1 for COPD in Chinese Population: A Prospective Cohort Study |
| Q33683010 | Predictors of mortality in elderly subjects with obstructive airway disease: the PILE score |
| Q43098736 | Prevalence and prognosis of chronic obstructive pulmonary disease among 8167 Middle Eastern patients with acute coronary syndrome. |
| Q57815175 | Prognostic value of C-reactive protein in chronic obstructive pulmonary disease |
| Q57955615 | Prognostic value of C-reactive protein, leukocytes, and vitamin d in severe chronic obstructive pulmonary disease |
| Q46253687 | Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. |
| Q34914760 | Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort |
| Q45059034 | Red blood cell distribution and survival in patients with chronic obstructive pulmonary disease |
| Q35493901 | Relationships of pulmonary function, inflammation, and T-cell activation and senescence in an HIV-infected cohort |
| Q36973036 | Restrictive pulmonary deficit is associated with inflammation in sub-optimally controlled obese diabetics |
| Q49346082 | Review of biomarkers to assess the effects of switching from cigarettes to modified risk tobacco products. |
| Q47655268 | Risk factors for osteoporosis in male patients with chronic obstructive pulmonary disease in Taiwan |
| Q90353425 | Risk of chronic obstructive pulmonary disease in healthy individuals with high C-reactive protein levels by smoking status: a population-based cohort study in Korea |
| Q42146567 | Role of Serum Interleukin 6, Albumin and C-Reactive Protein in COPD Patients |
| Q50602624 | Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial. |
| Q92068191 | Serum Alpha-1 Antitrypsin Levels and the Clinical Course of Chronic Obstructive Pulmonary Disease |
| Q39428853 | Serum C-reactive protein level and distribution in chronic obstructive pulmonary disease versus healthy controls: a case-control study from Iran. |
| Q37563167 | Serum C-reactive protein level in COPD patients stratified according to GOLD 2011 grading classification. |
| Q93150096 | Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial |
| Q92974918 | Serum inflammatory markers and nutritional status in patients with stable chronic obstructive pulmonary disease |
| Q44518503 | Seventeen year risk of all-cause and cause-specific mortality associated with C-reactive protein, fibrinogen and leukocyte count in men and women: the EPIC-Norfolk study |
| Q51159286 | Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. |
| Q36243216 | Simvastatin Suppresses Airway IL-17 and Upregulates IL-10 in Patients With Stable COPD. |
| Q37203479 | Simvastatin up-regulates adenosine deaminase and suppresses osteopontin expression in COPD patients through an IL-13-dependent mechanism |
| Q38174717 | Sleep-related disorders in chronic obstructive pulmonary disease |
| Q34805380 | Smoking cessation therapy with varenicline |
| Q35100841 | Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD. |
| Q37612872 | Specific networks of plasma acute phase reactants are associated with the severity of chronic obstructive pulmonary disease: a case-control study |
| Q42572130 | Statin use reduces decline in lung function: VA Normative Aging Study |
| Q38228514 | Statins as adjunct therapy in COPD: how do we cope after STATCOPE? |
| Q39857892 | Stress and inflammation: a biobehavioral approach for nursing research |
| Q37701187 | Study the association of chronic obstructive pulmonary disease with early endothelial dysfunction and its impact on cardiovascular system by estimating urinary albumin creatinine ratio |
| Q36960786 | Superoxide dismutase 3 polymorphism associated with reduced lung function in two large populations |
| Q34636461 | Surfactant protein D, Club cell protein 16, Pulmonary and activation-regulated chemokine, C-reactive protein, and Fibrinogen biomarker variation in chronic obstructive lung disease |
| Q38340124 | Systematic review of anaemia and inflammatory markers in chronic obstructive pulmonary disease |
| Q33831583 | Systemic Inflammation in Older Adults With Asthma-COPD Overlap Syndrome |
| Q48423263 | Systemic effects of nocturnal hypoxemia in patients with chronic obstructive pulmonary disease without obstructive sleep apnea syndrome |
| Q38006928 | Systemic inflammation and comorbidities in chronic obstructive pulmonary disease |
| Q42764765 | Systemic inflammation and progression of COPD. |
| Q33939195 | Systemic inflammation in chronic obstructive pulmonary disease: a population-based study |
| Q36956720 | Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease |
| Q37734257 | Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease |
| Q38109909 | The COPD Biomarker Qualification Consortium (CBQC). |
| Q41170536 | The Effect on Total Mortality of Adding Inhaled Corticosteroids to Long-Acting Bronchodilators for COPD: A Real Practice Analysis in Italy |
| Q58767290 | The Effects of Ramadan-Fasting (RF) on Inflammatory and Hematological Indices of Stable Chronic Obstructive Pulmonary Disease (COPD) Male Patients: A Pilot Study |
| Q38608866 | The Gut-Liver-Lung Axis. Modulation of the Innate Immune Response and Its Possible Role in Chronic Obstructive Pulmonary Disease |
| Q87695964 | The Importance of Neutrophil-to-Lymphocyte Ratio in Chronic Obstructive Pulmonary Disease |
| Q46049840 | The effects of ambient temperature variation on respiratory hospitalizations in summer, New York State |
| Q38965052 | The effects of atorvastatin on mustard-gas-exposed patients with chronic obstructive pulmonary disease: A randomized controlled trial |
| Q46725792 | The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease |
| Q37136637 | The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations |
| Q36300138 | The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases |
| Q46356950 | The impact of chronic obstructive pulmonary disease and smoking on mortality and kidney transplantation in end-stage kidney disease |
| Q37389399 | The importance of C-reactive protein and other inflammatory markers in patients with chronic obstructive pulmonary disease |
| Q33532293 | The influence of heart disease on characteristics, quality of life, use of health resources, and costs of COPD in primary care settings |
| Q37168309 | The repeatability of interleukin-6, tumor necrosis factor-alpha, and C-reactive protein in COPD patients over one year |
| Q39213635 | The role of inflammatory biomarkers in CHD-associated pulmonary hypertension in children. |
| Q49087290 | The role of interleukin-6 in pulmonary and systemic manifestations in a murine model of chronic obstructive pulmonary disease. |
| Q38077797 | The role of systemic inflammatory biomarkers to predict mortality in chronic obstructive pulmonary disease |
| Q38739067 | The use of cellular and molecular biomarkers to manage COPD exacerbations |
| Q42634551 | The value of blood cytokines and chemokines in assessing COPD. |
| Q36750478 | Three-year follow-up of Interleukin 6 and C-reactive protein in chronic obstructive pulmonary disease |
| Q45270152 | Triggering receptor in myeloid cells (TREM-1) specific expression in peripheral blood mononuclear cells of sepsis patients with acute cholangitis |
| Q36838782 | Update in chronic obstructive pulmonary disease 2006. |
| Q37129292 | Update in chronic obstructive pulmonary disease 2007. |
| Q34656726 | Update on the potential role of statins in chronic obstructive pulmonary disease and its co-morbidities. |
| Q34679282 | Utility of the combination of serum highly-sensitive C-reactive protein level at discharge and a risk index in predicting readmission for acute exacerbation of COPD. |
| Q37979248 | Vascular dysfunction in chronic obstructive pulmonary disease: current evidence and perspectives |
| Q37194104 | What is the impact of different spirometric criteria on the prevalence of spirometrically defined COPD and its comorbidities? Results from the population-based KORA study |
| Q33797611 | Will expanded ART use reduce the burden of HIV-associated chronic lung disease? |
| Q79702247 | [A prospective study of quality of life and treatment of chemotherapy-induced anaemia in lung cancer] |
| Q85045912 | [COPD: bronchial and systemic inflammation] |
| Q82707801 | [COPD: what is there beyond BODE index?] |
| Q84556831 | [Chronic obstructive pulmonary disease and cardiovascular disease] |
| Q82707696 | [Prognostic markers of COPD. Role of comorbidity] |
| Q54373353 | p38 Mitogen-activated protein kinase accelerates emphysema in mouse model of chronic obstructive pulmonary disease. |
Search more.